---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120673"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:54:43.963201+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront

## Summary
- Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.
- Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.
- Royalty rate subject to adjustments based on future aggregate net sales.
- Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap.

## SEC filing metadata
- accession: 0000950170-24-120673
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/0000950170-24-120673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/sndx-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120673
- JSON: https://secwatch.observer/filing/0000950170-24-120673.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.